COVID-19 Drug Associated APIs Market 2024: Share, Growth Drivers, Price, Key Manufacturer, Challenge | |
The COVID-19 Drug Associated APIs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2024-2033). Learn More On The COVID-19 Drug Associated APIs Market: https://www.thebusinessresearchcompany.com/report/covid19-drug-associated-api-global-market-report As delineated in The Business Research Company’s comprehensive analysis, the COVID-19 Drug Associated APIs Global Market Report for 2024 unveils a robust surge in the market size of COVID-19 drug-associated APIs. From its standing at $6.37 billion in 2024, the market is poised to ascend to $6.75 billion by the same year, boasting a noteworthy Compound Annual Growth Rate (CAGR) of 5.9%. This growth trajectory in the historical context stems from various factors including the escalating prevalence of COVID-19, heightened awareness surrounding treatment options, enhanced accessibility to COVID-19 drugs, burgeoning demand for prophylactic measures, governmental interventions, and the fortitude of supply chains. Projections indicate a continued ascension in the COVID-19 drug-associated APIs market size in the forthcoming years. By 2028, it is anticipated to soar to $8.52 billion, underpinned by a commendable CAGR of 6.0%. This anticipated growth in the forecast period is underpinned by the advent of novel COVID-19 drug modalities, a surge in clinical trials for COVID-19 drugs, heightened demand for COVID-19 vaccines, the emergence of variants, intensified vaccination campaigns, and a renewed emphasis on pandemic preparedness. Noteworthy trends in this period encompass the customization of API production, the diversification of API sources, the adoption of advanced manufacturing technologies, the integration of digitalization and data analytics, as well as a heightened focus on sustainability and green chemistry initiatives. High demand for antiretrovirals, antimalarials, sedatives, bronchodilators, and other respiratory drugs drives the demand for the active pharmaceutical ingredients (APIs) used in the production of COVID-19 drugs. Active pharmaceutical ingredients (APIs) are the biologically active components used in manufacturing pharmaceutical drugs. Remdesivir and Favipiravir are two common antiviral medications used currently for the treatment of COVID-19 patients. Remdesivir is a medication approved for emergency use in the USA and Japan for the treatment of COVID-19 patients. FDA has approved Airsupra (albuterol and budesonide) inhalation aerosol for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in patients with asthma 18 years of age and older. Favipiravir, which is used to treat influenza in Japan, has also shown a positive effect on COVID-19 patients. As COVID-19 is a respiratory ailment, the demand for bronchodilators spiked significantly. Therefore, the increasing demand for antivirals, antimalarials, and bronchodilators is projected to boost the demand for the COVID-19 drug associated APIs market over the forecast period. Get A Free Sample Of The Report (Includes Graphs And Tables): https://www.thebusinessresearchcompany.com/sample.aspx?id=3248&type=smp The covid-19 drug associated apis market covered in this report is segmented – 1) By Drug Class: Antimalarials, Bronchodilators, Antibiotics, Antivirals, Other Drug Class 2) By Synthesis Type: Synthetic, Biotech 3) By Business Mode: Captive API, Merchant API The covid-19 drug associated apis market report table of contents includes: 1. Executive Summary 2. COVID-19 Drug Associated APIs Market Characteristics 3. COVID-19 Drug Associated APIs Market Trends And Strategies 4. COVID-19 Drug Associated APIs Market - Macro Economic Scenario 5. Global COVID-19 Drug Associated APIs Market Size and Growth. ..... 31. Global COVID-19 Drug Associated APIs Market Competitive Benchmarking 32. Global COVID-19 Drug Associated APIs Market Competitive Dashboard 33. Key Mergers And Acquisitions In The COVID-19 Drug Associated APIs Market 34. COVID-19 Drug Associated APIs Market Future Outlook and Potential Analysis 35. Appendix | |
| Target State: All States Target City : All Cities Last Update : Feb 15, 2024 3:01 AM Number of Views: 92 | Item Owner : TBRC Contact Email: (None) Contact Phone: (None) |
| Friendly reminder: Click here to read some tips. | |